<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740947</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002211-28</org_study_id>
    <nct_id>NCT01740947</nct_id>
  </id_info>
  <brief_title>Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?</brief_title>
  <acronym>SELECT</acronym>
  <official_title>Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Jaap Bonjer, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Digestive Diseases Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD&#xD;
      can reduce clinical anastomotic leakage rate and its septic consequences as well as other&#xD;
      infectious complications. By reduction of septic complications long-term oncological outcome&#xD;
      might simultaneously improve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Infectious complications and especially anastomotic leakage severely impede the recuperation&#xD;
      of patients following colorectal cancer surgery. When the normal gut barrier fails such as in&#xD;
      anastomotic leakage, pathogenic microorganisms like Gram-negative bacteria enter the&#xD;
      circulation and may cause severe sepsis which is associated with considerable mortality.&#xD;
      Moreover, anastomotic leakage has a negative impact on colorectal cancer prognosis. Selective&#xD;
      decontamination of the digestive tract (SDD) is a prophylaxis regimen that employs oral&#xD;
      nonabsorbable antibiotics to eradicate pathogenic micro-organisms like Gram-negative&#xD;
      bacteria.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD&#xD;
      can reduce clinical anastomotic leakage rate and its septic consequences as well as other&#xD;
      infectious complications. By reduction of septic complications long-term oncological outcome&#xD;
      might simultaneously improve. Secondary objectives are a decline in reoperation rate,&#xD;
      in-hospital mortality, readmission rate, duration of hospital stay and ICU admission,&#xD;
      non-infectious complications, improvement of quality of life and reduction of costs.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A randomised multicenter clinical trial comparing perioperative SDD in addition to standard&#xD;
      antibiotic prophylaxis with standard antibiotic prophylaxis alone in patients with colorectal&#xD;
      cancer who undergo elective surgical resection with curative intent.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients 18 years or older are eligible for inclusion when they are diagnosed with colon or&#xD;
      rectal cancer without signs of distant metastases. Patients may be scheduled for either&#xD;
      laparoscopic or open resection with curative intent, including construction of an anastomosis&#xD;
      (either with or without diverting stoma). Patients are not eligible for inclusion in case of&#xD;
      concomitant metastases or acute obstruction.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Patients are randomly allocated for either perioperative SDD (intervention group) including&#xD;
      standard antibiotic prophylaxis or standard treatment (including standard antibiotic&#xD;
      prophylaxis alone) (control group). The solution containing SDD is orally taken 4 times&#xD;
      daily, starting 3 days before surgery and continued until normal bowel passage or at least 3&#xD;
      days after surgery. Both groups receive a single preoperative intravenous dose of 1000 mg&#xD;
      Cefazoline and 500 mg Metronidazole, which is the current standard antibiotic prophylaxis.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The main study parameter is anastomotic leakage. The research hypothesis refers to an&#xD;
      estimated decrease in anastomotic leakage rate in the SDD treated group (from 9% to 4%). As&#xD;
      anastomotic leakage has been shown unfavourable forlong term oncological outcome, we presume&#xD;
      an improvement in disease free survival, which serves as important secondary endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Superiority was no longer attainable&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anastomotic leakage and/or abscess</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>clinical and/or radiological evidence of anastomotic dehiscence requiring surgical or radiological (re)intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 and 5 years after inclusion</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Other postoperative infectious complications</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>pneumonia, urinary tract infections, surgical site infections, wound dehiscence, (remote) intraabdominal abscess</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-infectious complications</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>cardiac failure, cerebrovascular events, deep venous thrombosis</description>
  </other_outcome>
  <other_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>30 days postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Readmission rate</measure>
    <time_frame>5 years postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>5 years postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>30 days postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (quality adjusted life years)</measure>
    <time_frame>2 years postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>In hospital and out-of-hospital costs</measure>
    <time_frame>5 years postoperatively</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment for colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective decontamination of the digestive tract (SDD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.&#xD;
SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)</intervention_name>
    <description>SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B</description>
    <arm_group_label>Selective decontamination of the digestive tract (SDD)</arm_group_label>
    <other_name>SDD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective colon and rectal cancer surgery with primary anastomosis&#xD;
&#xD;
          -  Or elective colorectal surgery for suspected carcinoma&#xD;
&#xD;
          -  No evidence of distant metastases (preoperative CT-abdomen and X-thorax or CTthorax)&#xD;
&#xD;
          -  Procedure either with or without diverting stoma&#xD;
&#xD;
          -  Both laparoscopic and open surgery&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous colorectal malignancy&#xD;
&#xD;
          -  Current malignancy which is now undergoing treatment&#xD;
&#xD;
          -  Inflammatory bowel disease (Crohn's disease or ulcerative colitis)&#xD;
&#xD;
          -  Previous surgery for diverticular disease&#xD;
&#xD;
          -  Performance status ASA 4 or higher (American Society for Anaesthesiologists)&#xD;
&#xD;
          -  Expected adverse reactions/allergies for study medication&#xD;
&#xD;
          -  Prednisone use &gt; 5 mg per day&#xD;
&#xD;
          -  Familial adenomatous polyposis coli (FAP; Lynch syndrome), Hereditary Non Polyposis&#xD;
             Colorectal Cancer (HNPCC)&#xD;
&#xD;
          -  Mental disorder/unable to give informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.J. Bonjer, Md, PhD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G.S.A. Abis, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Slotervaart Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WestFries Gasthuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>H. Jaap Bonjer, PhD</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Selective decontamination of the digestive tract</keyword>
  <keyword>anastomotic leakage</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Colistin</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

